Gideon Sorlelodum Alex

Ms. Gideon Sorlelodum Alex

Anatomy, University of Port Harcourt, Port Harcourt, Rivers, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Journal of Neuroscience and Neurological Disorders
Verified
Journal Article
Open access
PDF file
GAGideon Sorlelodum Alex
Gideon Sorlelodum Alex
OOOlanrewaju Oluwaseun Oke
Olanrewaju Oluwaseun Oke
JEJoy Wilberforce Ekokojide
Joy Wilberforce Ekokojide
TGTolulope Judah Gbayisomore
Tolulope Judah Gbayisomore
MAMartina C. Anene-Ogbe
Martina C. Anene-Ogbe
JYJoshua Ayodele Yusuf
Joshua Ayodele Yusuf
Background: The study of new neuron formation in the adult brain has sparked controversy and ignited interest among scientists in recent times, these include its occurrence and location in the adult human brain, functional significance, variation in study methods, translation from animal model to human, and ethical challenges involving neural stem cell research. Aim: To provide a comprehensive understanding of adult neurogenesis, functional significance, and challenges and explore the latest advances in the study of adult neurogenesis. Methodology: An extensive and systematic search of electronic databases (Medline, Scopus, Web of Science) was conducted using keywords related to adult neurogenesis and techniques involved in its study. Results: The mechanism of adult neurogenesis was found to occur in specific brain regions such as the subgranular zone of the dentate gyrus and subventricular zone of the lateral ventricle. Adult neurogenesis is vital neural plasticity, providing a potential mechanism for the brain to adapt and reorganize in response to environmental cues and experiences. Cutting-edge research and sophisticated imaging techniques, such as two-photon microscopy, MRI, optogenetic, and stem-cell-based therapies have provided deeper insight into the study of adult neurogenesis. Conclusion: The study of neurogenesis is important for understanding nervous system development, physiology, pathology, and exploring neuroplasticity. Its advancement is challenged by some ethical concerns regarding embryonic, pluripotent stem cells, and the need for safe, and noninvasive study methods. Although recent breakthroughs in neuroimaging, microscopic techniques, and genetic tools are aiding real-time study of adult neurogenesis.

27 March 2025 in Brain and Spine
Verified
Journal Article
Open access
GAGideon Sorlelodum Alex
Gideon Sorlelodum Alex
OPOluwatobiloba Israel Popoola
Oluwatobiloba Israel Popoola
Inibehe Ime OkonInibehe Ime Okon
Inibehe Ime Okon

30 April 2024 in INNOSC Theranostics and Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
TGTolulope Judah Gbayisomore
Tolulope Judah Gbayisomore
KIKingsley Afoke Iteire
Kingsley Afoke Iteire
Inibehe Ime OkonInibehe Ime Okon
Inibehe Ime Okon
IEIsunu Lucky Efe
Isunu Lucky Efe
OFOkikiola Oyindamola Falua
Okikiola Oyindamola Falua
AIAbdul-Hanan Saani Inusah
Abdul-Hanan Saani Inusah
Neurological conditions, such as Alzheimer’s disease (AD) and tau-related pathologies, represent a substantial worldwide health dilemma. This review explores recent advancements and challenges in single-domain antibody (VHH)-based strategies targeting beta-secretase 1 (BACE1) inhibition and tau-related therapeutics. The methodology adopted in this study involved a comprehensive search of databases (e.g., Scopus, PubMed, and Google Scholar), with recent articles cited to provide an up-to-date overview. The research examines the limitations of current AD treatments, emphasizing the need for innovative techniques. We, further, discuss potential gene transfer methods using adeno-associated virus-based vectors for central nervous system delivery of single-domain immunoglobins/antibodies (VHHs) to inhibit BACE1. In addition, insights into anti-tau therapeutics, including passive immunization and active vaccines, offer novel insights into research. These findings hold implications for the redesign of therapies for neurodegenerative disorders and the advancement of clinical understanding.

17 February 2025
Verified
Book Chapter
Closed access
Adejoke MemuduAdejoke Memudu
Adejoke Memudu
BOBaliqis Olukade
Baliqis Olukade
KNKenechukwu Emmanuel Nwanama
Kenechukwu Emmanuel Nwanama
GAGideon Sorlelodum Alex
Gideon Sorlelodum Alex

28 April 2025 in Advanced Neurology
Verified
Journal Article
Open access
PDF file
GAGideon Sorlelodum Alex
Gideon Sorlelodum Alex
MAMartina C. Anene-Ogbe
Martina C. Anene-Ogbe
GFGlory Farounbi
Glory Farounbi
TGTolulope Judah Gbayisomore
Tolulope Judah Gbayisomore
Adejoke MemuduAdejoke Memudu
Adejoke Memudu
Alzheimer’s disease (AD) is the most common cause of age-related dementia and death, resulting from the aggregation of tau protein into insoluble neurofibrillary tangles (NFTs) composed of paired helical filaments and straight filaments. Graphene quantum dots (GQDs), a unique form of nanoparticles, have emerged as a crucial tool for the detection and diagnosis of AD. They are considered attractive due to their fluorescence-emitting capabilities, nanoscale size, chemical stability, solubility, and ease of synthesis. In this review, we investigated the potential of GQDs as a therapeutic tool in AD intervention, highlighting their recent developments, challenges, and future directions. A comprehensive and systematic search was conducted across electronic databases (Scopus, PubMed, Google Scholar, and Medline) for recent and up-to-date articles related to the keywords: “Alzheimer’s disease,” “graphene quantum dots,” “nanoparticles,” and “neuroscience.” Our findings indicate that QDs possess the ability to cross the blood–brain barrier, reduce disease symptoms, and facilitate drug delivery, cell labeling, and neuronal regeneration. In addition, early identification, prevention, and disassembly of tau protein aggregation in AD can be achieved using GQDs. In conclusion, the application of GQDs to improve the progression of AD neuropathology by disintegrating NFTs of tau protein presents a promising approach for diagnostic research in AD. The limitations of GQDs, particularly their long-term exposure to the brain, need to be thoroughly investigated. This includes minimizing the side effects through a multidisciplinary translational neuroscience approach for therapeutic applications in clinical trials.

3 December 2025 in Advanced Neurology
Verified
Journal Article
Open access
PDF file
TGTolulope Judah Gbayisomore
Tolulope Judah Gbayisomore
GAGideon Sorlelodum Alex
Gideon Sorlelodum Alex
KIKingsley Afoke Iteire
Kingsley Afoke Iteire
OAOluwafemi Abidemi Adedotun
Oluwafemi Abidemi Adedotun
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder, and currently available pharmacological interventions provide only limited symptomatic relief and do not halt disease progression, emphasizing the need for alternative therapeutics. Herbal medicine, particularly from regions rich in plant biodiversity such as Africa, is gaining attention for its cognitive-enhancing and neuroprotective potential. This study reviews the potential benefits of common medicinal plants used in Africa for the treatment of AD, their traditional uses, phytochemical properties, and mechanisms of action reported in pre-clinical/clinical studies. A comprehensive search targeting 19 medicinal plant species with potential benefits for AD treatment was conducted across PubMed, Google Scholar, and African Journals Online up to 2025 using specific keywords related to African medicinal plants and AD. This review focused on medicinal plants utilized in African herbal medicine. However, some species included in this review are non-native but have been introduced, cultivated, and integrated into local herbal practices in Africa. Plants such as Persea americana, Cuminum cyminum, Huperzia serrata, and Astragalus membranaceus exhibit antioxidant, anti-inflammatory, and anticholinesterase activities, modulating major AD pathological processes, such as amyloid-beta aggregation, oxidative stress, and cholinergic dysfunction. Preclinical evidence suggests neuroprotective effects in animal models, while clinical data, though limited, show cognitive benefits. Regulatory challenges and the lack of standardization in the development and dosing of herbal extracts remain significant barriers to the clinical translation of African herbal medicine. Hence, further research and clinical validation, alongside the development of regulatory frameworks and standardization protocols, are needed to bridge the gap between traditional knowledge and evidence-based medicine and to develop effective, accessible, and sustainable AD treatment options.